Goldman Sachs Maintains Sell on Cytek Biosciences, Lowers Price Target to $3
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Goldman Sachs analyst Matthew Sykes maintains Cytek Biosciences (NASDAQ:CTKB) with a Sell and lowers the price target from $3.5 to $3.
Goldman Sachs analyst Matthew Sykes maintains Cytek Biosciences (NASDAQ:CTKB) with a Sell and lowers the price target from $3.5 to $3.